The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
#SOHO2024: Hodgkin lymphoma and T-cell lymphoma
To update you on the exciting content presented at the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting, we have collated our social media coverage. Catch up on our live social media coverage relating to Hodgkin lymphoma and T-cell lymphoma below.
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 9, 2024
Stephen M Ansell, @MayoClinic, discusses whether ABVD and BEACOPP are still relevant for the treatment of advanced stage Hodgkin #lymphoma. He believes that A(B)VD chemotherapy still has a role for low-risk patients, while younger patients or those with… pic.twitter.com/ka5lMu1N9L
CONGRESS | #SOHO2024 | POSTER
— Lymphoma Hub (@lymphomahub) September 10, 2024
Steven Horwitz @MSKCancerCenter presents the VALENTINE-PTCL01 study investigating valemetostat in pts with R/R PTCL. N=133 (n=119 for efficacy data); CT-based ORR=43.7%; median DoR=11.9 mo; Grade ≥3 TEAE=57.9%.#lymphoma #lymsm #MedicalCongress pic.twitter.com/Pu8ZOgVGHp
CONGRESS | #SOHO2024@StefanBartaMD, @PennMedicine, discusses immunotherapies for T-cell #lymphoma, which are primarily categorized into those targeting surface antigens and those targeting immune checkpoints. He highlights various strategies to overcome the challenges of CAR… pic.twitter.com/sLXKK6sOhq
— Lymphoma Hub (@lymphomahub) September 9, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content